



**Supplementary Fig. 2.** Survival outcomes in patients aged > 65 years by first-line (1L) regimen (FCR [fludarabine, cyclophosphamide, and rituximab] vs. GC [obinutuzumab and chlorambucil]). (A) Progression-free survival (PFS), and (B) overall survival (OS). CI, confidence interval; NR, not reached.